Immunogenicity and Protection from a Single Dose of Internationally available killed oral Cholera Vaccine: a systematic review and meta-analysis

Hdl Handle:
http://hdl.handle.net/10144/619049
Title:
Immunogenicity and Protection from a Single Dose of Internationally available killed oral Cholera Vaccine: a systematic review and meta-analysis
Authors:
Lopez, AL; Deen, J; Azman, AS; Luquero, FJ; Kanungo, S; Dutta, S; von Seidlein, L; Sack, DA
Journal:
Clinical Infectious Diseases
Abstract:
In addition to improved water supply and sanitation, the two-dose killed oral cholera vaccine (OCV) is an important tool for the prevention and control of cholera. We aimed to document the immunogenicity and protection (efficacy and effectiveness) conferred by a single OCV dose against cholera. The meta-analysis showed an estimated 73% and 77% of individuals seroconverted to the Ogawa and Inaba serotypes, respectively, after an OCV first dose. The estimates of single-dose vaccine protection from available studies are 87% at 2 months decreasing to 33% at 2 years. Current immunologic and clinical data suggest that protection conferred by a single dose of killed OCV may be sufficient to reduce short-term risk in outbreaks or other high-risk settings, which may be especially useful when vaccine supply is limited. However, until more data suggests otherwise, a second dose should be given as soon as circumstances allow to ensure robust protection.
Publisher:
Oxford University Press
Issue Date:
21-Nov-2017
URI:
http://hdl.handle.net/10144/619049
DOI:
10.1093/cid/cix1039
PubMed ID:
29177437
Submitted date:
2017-12-15
Language:
en
ISSN:
1537-6591
Appears in Collections:
Vaccination

Full metadata record

DC FieldValue Language
dc.contributor.authorLopez, ALen
dc.contributor.authorDeen, Jen
dc.contributor.authorAzman, ASen
dc.contributor.authorLuquero, FJen
dc.contributor.authorKanungo, Sen
dc.contributor.authorDutta, Sen
dc.contributor.authorvon Seidlein, Len
dc.contributor.authorSack, DAen
dc.date.accessioned2017-12-20T23:51:51Z-
dc.date.available2017-12-20T23:51:51Z-
dc.date.issued2017-11-21-
dc.date.submitted2017-12-15-
dc.identifier.citationImmunogenicity and Protection from a Single Dose of Internationally available killed oral Cholera Vaccine: a systematic review and meta-analysis. 2017 Clin. Infect. Dis.en
dc.identifier.issn1537-6591-
dc.identifier.pmid29177437-
dc.identifier.doi10.1093/cid/cix1039-
dc.identifier.urihttp://hdl.handle.net/10144/619049-
dc.description.abstractIn addition to improved water supply and sanitation, the two-dose killed oral cholera vaccine (OCV) is an important tool for the prevention and control of cholera. We aimed to document the immunogenicity and protection (efficacy and effectiveness) conferred by a single OCV dose against cholera. The meta-analysis showed an estimated 73% and 77% of individuals seroconverted to the Ogawa and Inaba serotypes, respectively, after an OCV first dose. The estimates of single-dose vaccine protection from available studies are 87% at 2 months decreasing to 33% at 2 years. Current immunologic and clinical data suggest that protection conferred by a single dose of killed OCV may be sufficient to reduce short-term risk in outbreaks or other high-risk settings, which may be especially useful when vaccine supply is limited. However, until more data suggests otherwise, a second dose should be given as soon as circumstances allow to ensure robust protection.en
dc.language.isoenen
dc.publisherOxford University Pressen
dc.rightsArchived with thanks to Oxford University Press and the Infectious Disease Society of America.en
dc.titleImmunogenicity and Protection from a Single Dose of Internationally available killed oral Cholera Vaccine: a systematic review and meta-analysisen
dc.identifier.journalClinical Infectious Diseasesen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.